The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Goserelin (Primary) ; Ribociclib (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms TEEL
- 18 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 16 May 2017 Status changed from suspended to active, no longer recruiting.
- 27 Dec 2016 Status changed from recruiting to suspended.